Swedish biopharmaceutical company Mendus AB (STO:IMMU) on Thursday reported positive two-year follow-up data from the ALISON Phase 1 trial, confirming the safety, tolerability and feasibility of vididencel as an active immunotherapy in high-risk ovarian cancer.

Eight of the 17 treated patients are still alive beyond the two-year mark.

The trial, conducted by the University Medical Center Groningen (UMCG) in the Netherlands, showed that improved tumour-directed immune responses following vididencel treatment were associated with better survival outcomes.

At a median follow-up of 26 months, stable disease was observed in 20% of patients without immune responses and 42% of those with responses, including two patients who have surpassed three and a half years of follow-up. No product-related serious side effects were reported, supporting vididencel's strong safety profile.

The results position the therapy as a viable candidate for combination with other treatments such as PARP inhibitors, immune checkpoint inhibitors and T cell engagers.

Mendus and UMCG are engaged in a multi-year collaboration focused on advancing novel immunotherapies for gynaecological cancers. Further clinical development of the gynaecological cancer programme will depend on future partnering.